Cargando…

Guideline-directed medical therapy is similarly effective in heart failure with mildly reduced ejection fraction

AIMS: Current guidelines recommend that disease-modifying pharmacological therapies may be considered for patients who have heart failure with mildly reduced ejection fraction (HFmrEF). We aimed to describe the characteristics, outcomes, provision of pharmacological therapies and dose-related associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Straw, Sam, Cole, Charlotte A., McGinlay, Melanie, Drozd, Michael, Slater, Thomas A., Lowry, Judith E., Paton, Maria F., Levelt, Eylem, Cubbon, Richard M., Kearney, Mark T., Witte, Klaus K., Gierula, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849301/ https://www.ncbi.nlm.nih.gov/pubmed/35781605 http://dx.doi.org/10.1007/s00392-022-02053-8

Ejemplares similares

Effect of disease‐modifying agents and their association with mortality in multi‐morbid patients with heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2020)

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2021)

Reduction of heart failure guideline‐directed medication during hospitalization: prevalence, risk factors, and outcomes
por: Palin, Victoria, et al.
Publicado: (2022)

Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure
por: Gierula, John, et al.
Publicado: (2022)

Prioritizing symptom management in the treatment of chronic heart failure
por: Koshy, Aaron O., et al.
Publicado: (2020)

Suboptimal Dosing of β-Blockers in Chronic Heart Failure: A Missed Opportunity?
por: McGinlay, Melanie, et al.
Publicado: (2022)

Personalised reprogramming to prevent progressive pacemaker-related left ventricular dysfunction: A phase II randomised, controlled clinical trial
por: Paton, Maria F., et al.
Publicado: (2021)

Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study
por: Kearney, Jessica, et al.
Publicado: (2021)

Association of heart failure and its comorbidities with loss of life expectancy
por: Drozd, Michael, et al.
Publicado: (2021)

Ischemic Heart Disease Modifies the Association of Atrial Fibrillation With Mortality in Heart Failure With Reduced Ejection Fraction
por: Mercer, Ben N., et al.
Publicado: (2018)

Prevalence and Predictors of Sepsis Death in Patients With Chronic Heart Failure and Reduced Left Ventricular Ejection Fraction
por: Walker, Andrew M. N., et al.
Publicado: (2018)

Diabetes mellitus and the causes of hospitalisation in people with heart failure
por: Malik, Anam, et al.
Publicado: (2022)

Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data
por: Straw, Sam, et al.
Publicado: (2021)

Correction: Advanced care planning during the COVID-19 pandemic: ceiling of care decisions and their implications for observational data
por: Straw, Sam, et al.
Publicado: (2022)

Vitamin D deficiency is an independent predictor of mortality in patients with chronic heart failure
por: Cubbon, Richard M., et al.
Publicado: (2018)

Relationship Among Diabetes, Obesity, and Cardiovascular Disease Phenotypes: A UK Biobank Cohort Study
por: Brown, Oliver I., et al.
Publicado: (2023)

Unique Transcriptome Signature Distinguishes Patients With Heart Failure With Myopathy
por: Caspi, Talia, et al.
Publicado: (2020)

Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study
por: Drozd, Michael, et al.
Publicado: (2021)

Cardiovascular magnetic resonance phenotyping of heart failure with mildly reduced ejection fraction
por: Brown, Louise A E, et al.
Publicado: (2022)

Atrial secondary mitral regurgitation: prevalence, characteristics, management, and long-term outcomes
por: Straw, Sam, et al.
Publicado: (2023)

Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification
por: Cubbon, Richard M, et al.
Publicado: (2016)

Efficacy of guideline‐directed medical treatment in heart failure with mildly reduced ejection fraction
por: Zhang, Xinxin, et al.
Publicado: (2022)

Optimising pacemaker therapy and medical therapy in pacemaker patients for heart failure: protocol for the OPT-PACE randomised controlled trial
por: Paton, Maria F, et al.
Publicado: (2019)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
por: Thirunavukarasu, Sharmaine, et al.
Publicado: (2021)

The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study
por: Mahmod, Masliza, et al.
Publicado: (2018)

Effects of Vitamin D on Cardiac Function in Patients With Chronic HF: The VINDICATE Study
por: Witte, Klaus K., et al.
Publicado: (2016)

Risk stratification in heart failure with mild reduced ejection fraction
por: Magrì, Damiano, et al.
Publicado: (2020)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Vascular Dysfunction Predicts Future Deterioration of Left Ventricular Ejection Fraction in Patients with Heart Failure with Mildly Reduced Ejection Fraction
por: Kishimoto, Shinji, et al.
Publicado: (2021)

Evaluation of Adherence to Guideline for Heart Failure with Reduced Ejection Fraction in Heart Failure with Preserved Ejection Fraction and with or without Atrial Fibrillation
por: Ahn, Min-Soo, et al.
Publicado: (2021)

Total 25-Hydroxyvitamin D Is an Independent Marker of Left Ventricular Ejection Fraction in Heart Failure with Reduced and Mildly Reduced Ejection Fraction
por: Szabo, Timea Magdolna, et al.
Publicado: (2023)

Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
por: Talha, Khawaja M., et al.
Publicado: (2022)

Systemic Inflammation Is Associated With Future Risk of Fatal Infection: An Observational Cohort Study
por: Drozd, Michael, et al.
Publicado: (2022)

Chronic heart failure with diabetes mellitus is characterized by a severe skeletal muscle pathology
por: Garnham, Jack O., et al.
Publicado: (2019)

Impact of Updated Guidelines on Diastolic Dysfunction in Patients with Preserved Ejection Fraction
por: Yoon, Hyun Ju
Publicado: (2021)

Quantifying the relationship and contribution of mitochondrial respiration to systemic exercise limitation in heart failure
por: Knuiman, Pim, et al.
Publicado: (2021)

Divergent skeletal muscle mitochondrial phenotype between male and female patients with chronic heart failure
por: Garnham, Jack O., et al.
Publicado: (2019)

Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations
por: Arvanitaki, Alexandra, et al.
Publicado: (2020)

The Prognostic Value of Anemia in Patients with Preserved, Mildly Reduced and Recovered Ejection Fraction
por: Pintér, Anita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ts8juhtql2ifmdvg7euc5nnl3m